Management of Multiple Purulent Skin Abscesses
For multiple abscesses with purulent drainage involving both legs and one arm, you must perform incision and drainage on all accessible sites AND prescribe antibiotics active against CA-MRSA, as this represents severe/extensive disease involving multiple sites of infection. 1
Primary Treatment Approach
Incision and drainage remains the cornerstone of treatment for all drainable abscesses 2, 1. However, your patient clearly meets criteria requiring adjunctive antibiotic therapy because they have "severe or extensive disease involving multiple sites of infection" 1, 2.
Why Antibiotics Are Mandatory Here
The IDSA guidelines explicitly state that antibiotic therapy is recommended for abscesses with:
- Severe or extensive disease (involving multiple sites of infection)
- Rapid progression with associated cellulitis
- Signs of systemic illness
- Associated comorbidities or immunosuppression
- Extremes of age
- Lack of response to I&D alone 2, 1, 2
Your patient has multiple sites (both legs + one arm), which automatically qualifies them for antibiotics regardless of other factors.
Antibiotic Selection for Outpatient Management
First-line oral antibiotic options for CA-MRSA coverage (choose ONE):
- Clindamycin 300-450 mg PO three times daily (A-I evidence) 1
- TMP-SMX 1-2 double-strength tablets PO twice daily (A-II evidence) 1
- Doxycycline 100 mg PO twice daily (A-II evidence) 1
- Minocycline 200 mg × 1, then 100 mg PO twice daily (A-II evidence) 1
Choosing Between These Options
- Clindamycin has the strongest evidence (A-I) and covers both CA-MRSA and streptococci, but carries higher risk of C. difficile infection 1
- TMP-SMX or tetracyclines require adding a beta-lactam (like amoxicillin 500 mg TID) if you're concerned about streptococcal coverage 1, 2
- For purulent infections (which yours are), empirical streptococcal coverage is likely unnecessary 1
Duration: 5-10 days, individualized based on clinical response 1, 2
Critical Pitfalls to Avoid
Do NOT Use Rifampin
Rifampin as single agent or adjunctive therapy for SSTI is not recommended (A-III) 1, 2, 1. Despite its in vitro activity, there's no evidence of benefit and high risk of resistance development.
Assess for Hospitalization Criteria
If your patient has ANY of the following, they need inpatient IV therapy:
- Systemic signs of infection (fever, tachycardia, hypotension)
- Rapidly progressive infection despite oral antibiotics
- Immunosuppression or significant comorbidities
- Inability to tolerate oral medications
- Signs of deeper infection (necrotizing fasciitis, myositis) 1, 3
For hospitalized patients, use IV vancomycin (A-I), linezolid 600 mg IV/PO twice daily (A-I), or daptomycin 4 mg/kg IV daily (A-I) 1
Incision and Drainage Technique Considerations
Recent evidence challenges traditional practices:
- Avoid routine packing - it increases pain without improving outcomes 4
- Irrigation after I&D is controversial; only 48% of providers routinely use it 5
- Wound cultures are not routinely necessary unless patient fails initial therapy or has risk factors for unusual organisms 1, 3
Follow-Up Strategy
- Reassess at 48-72 hours to ensure clinical improvement 5
- If no improvement or worsening: obtain cultures, consider hospitalization, and broaden coverage 1
- Recurrence is common (up to 29% of cases) 6; consider decolonization regimen if recurrent: intranasal mupirocin twice daily + daily chlorhexidine washes for 5 days 3, 7
Special Populations
- Pregnant women (3rd trimester): Avoid TMP-SMX (category C/D); use clindamycin or beta-lactam 1
- Children <8 years: Avoid tetracyclines; use clindamycin 10-13 mg/kg/dose PO every 6-8 hours 1
- Elderly on ACE inhibitors/ARBs: Use TMP-SMX cautiously due to hyperkalemia risk 1
Bottom line: Multiple abscesses = I&D all sites + oral CA-MRSA antibiotics for 5-10 days. Clindamycin monotherapy or TMP-SMX are your best first-line choices.